Skip to main content
. 2021 Jun 21;61(6):927–935. doi: 10.1111/head.14138

FIGURE 2.

FIGURE 2

Flow of patients through the DBTP of the study. *All randomized patients received ≥1 dose of the investigational product and had ≥1 monthly migraine day measurement and were included in the efficacy and safety analysis sets. DBTP, double‐blind treatment phase; N, total number of patients; n, subset of patients